Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark

References

• DrummondMFO´BrienBStoddartGLTorranceGWMethods for the Economic Evaluation of Health Care Programmes2nd edOxfordOxford Medical Publications, Oxford University Press1997
   Google Scholar
• GarrisonLTowseAThe drug budget silo mentality in Europe: an overviewValue Health20036Suppl1S1S912846921
   PubMed Web of Science ®Google Scholar
• PanteliDEckhardtHNoltingABusseRKuligMFrom market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countriesHealth Res Policy Syst2015133926407728
   PubMed Web of Science ®Google Scholar
• CammAJKirchhofPLipGYEuropean Heart Rhythm AssociationEuropean Association for Cardio-Thoracic SurgeryGuidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)Eur Heart J201031192369242920802247
   PubMed Web of Science ®Google Scholar
• ColillaSCrowAPetkunWSingerDESimonTLiuXEstimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult populationAm J Cardiol201311281142114723831166
   PubMed Web of Science ®Google Scholar
• SavelievaICammJUpdate on atrial fibrillation: part IClin Cardiol2008312556218257025
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPBraunwaldEComparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trialsLancet201438395596224315724
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSRE-LY Steering Committee and InvestigatorsDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJROCKET AF InvestigatorsRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJARISTOTLE Committees and InvestigatorsApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• GiuglianoRPRuffCTBraunwaldEfor the ENGAGE AF-TIMI 48 InvestigatorsEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med2013369222093210424251359
   PubMed Web of Science ®Google Scholar
• Danish source on primary sector drug prices [webpage on the Internet] Available from: www.medicinpriser.dkAccessed June 15, 2017
   Google Scholar
• Danish Health Authorities (Sundhedsstyrelsen)Egenbehandling ved kroniske sygdomme - anbefalinger, der understøtter udbredelse [Treatment of chronic diseases – recommendation that support implementation]Copenhagen2012 Danish
   Google Scholar
• LangkildeLKBergholdt AsmussenMOvergaardMCost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in DenmarkJ Med Econ201215469570322397590
   PubMedGoogle Scholar
• VestergaardASEhlersLHA health economic evaluation of stroke prevention in atrial fibrillation: guideline adherence versus the observed treatment strategy prior to 2012 in DenmarkPharmacoeconomics201533996797925943684
   PubMed Web of Science ®Google Scholar
• Organisation of General Practitioners in Denmark (PLO)Takstkatalog [Charge catalogue for the general practice in Denmark]PLOCopenhagen2015 Danish
   Google Scholar
• Rådet for Anvendelse af Dyr Sygehusmedicin (RADS). [Council on the Use of Expensive Hospital Medicine (RADS)]Behandlingsvejledning for oral antikoagulationsbehandling ved non-valvulær atrieflimren [Treatment recommendation for oral anticoagulation therapy]Copenhagen2016 Danish
   Google Scholar
• JakobsenMKolodziejczykCFredslundEKPoulsenPBDybroLJohnsenSPSocietal costs of first-incident ischemic stroke in patients with atrial fibrillation – a Danish nationwide registry studyValue Health201619441341827325333
   PubMed Web of Science ®Google Scholar
• JakobsenMKolodziejczykCKlausen FredslundEPoulsenPBDybroLPaaske JohnsenSCosts of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation – a nationwide cohort studyBMC Health Serv Res201717139828606079
   PubMed Web of Science ®Google Scholar
• WisløffTHagenGKlempMEconomic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillationPharmacoeconomics201432660161224715603
   PubMed Web of Science ®Google Scholar
• LipGYKongnakornTPhatakHCost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillationClin Ther201436219221024508420
   PubMed Web of Science ®Google Scholar
• MenschAStockSStollenwerkBMüllerDCost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillationPharmacoeconomics201533327128325404426
   PubMed Web of Science ®Google Scholar
• MillerJDYeXLenhartGMCost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the USClinicoecon Outcomes Res2016821522627284259
   PubMed Web of Science ®Google Scholar
• BrunettiNAGennaroLDCaldarolaPDirect oral anticoagulants for the prevention of thromboembolic complications of atrial fibrillation: the more you pay, the less you spend?Int J Cardiol201724123824028363685
   PubMed Web of Science ®Google Scholar
• DeitelzweigSAminAJingYMedical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trialsJ Med Econ201215477678522449118
   PubMedGoogle Scholar
• DeitelzweigSAminAJingYMedical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trialsJ Med Econ20131691163116823869941
   PubMedGoogle Scholar
• DeitelzweigSAminAJingYMedical costs of oral anticoagulants vs warfarin for atrial fibrillation patients with different stroke risksCardiol Ther20132216517025135394
   PubMedGoogle Scholar
• AminAStokesMMakenbaevaDWiederkehrDWuNLawrenceJHEstimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient populationJ Med Econ2014171177178125133458
   PubMedGoogle Scholar
• SuttonAAdesAECooperNAbramsKUse of indirect and mixed treatment comparisons for technology assessmentPharmacoeconomics200826975376718767896
   PubMed Web of Science ®Google Scholar
• LambertsMStaerkLOlesenJBMajor bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patientsJ Am Heart Assoc201762 pii: e004517
   PubMed Web of Science ®Google Scholar
• HalvorsenSGhanimaWFride TveteIA nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulantsEur Heart J Cardiovasc Pharmacother201731283627680880
   PubMed Web of Science ®Google Scholar
• StaerkLFosbølELLipGYHIschaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort studyEur Heart J2017381290791527742807
   PubMed Web of Science ®Google Scholar
• YaoXAbrahamNSSangaralinghamLREffectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillationJ Am Heart Assoc201656 pii: e003725
   Web of Science ®Google Scholar
• LipGYKeshishianAKambleSReal-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysisThromb Haemost2016116597598627538358
   PubMed Web of Science ®Google Scholar
• WallentinLLopesRDHannaMApixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) investigators. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillationCirculation2013127222166217623640971
   PubMed Web of Science ®Google Scholar